Real-world resource use and costs of adjuvant treatment for stage III colon cancer.

about

A practical guide for using registry data to inform decisions about the cost effectiveness of new cancer drugs: lessons learned from the PHAROS registry.Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer.

P2860

Q30887169-8D788D2B-1BE0-47E3-A1F2-262324BFE748 Q55007703-5280185F-ACCE-4619-B3BD-A67F793FFAAC

P2860

Real-world resource use and costs of adjuvant treatment for stage III colon cancer.

Item

http://www.wikidata.org/entity/Q38174218

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Real-world resource use and costs of adjuvant treatment for stage III colon cancer.

@en

type

Item

label

Real-world resource use and costs of adjuvant treatment for stage III colon cancer.

@en

prefLabel

Real-world resource use and costs of adjuvant treatment for stage III colon cancer.

@en

P1476

Real-world resource use and costs of adjuvant treatment for stage III colon cancer.

@en

P2093

C A Uyl-de Groot

http://www.w3.org/2001/XMLSchema#string

C J A Punt

http://www.w3.org/2001/XMLSchema#string

C W M van Gils

http://www.w3.org/2001/XMLSchema#string

M Koopman

http://www.w3.org/2001/XMLSchema#string

S S Tan

http://www.w3.org/2001/XMLSchema#string

S de Groot

http://www.w3.org/2001/XMLSchema#string

W K Redekop

http://www.w3.org/2001/XMLSchema#string

P2860

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.

Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.

Capecitabine as adjuvant treatment for stage III colon cancer.

Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.

P304

321-332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ECC.12154

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259489319

http://www.w3.org/2001/XMLSchema#string

P698

24372941

http://www.w3.org/2001/XMLSchema#string

Real-world resource use and costs of adjuvant treatment for stage III colon cancer.

about

P2860

P2860

Real-world resource use and costs of adjuvant treatment for stage III colon cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698